JP2022509358A5 - - Google Patents

Info

Publication number
JP2022509358A5
JP2022509358A5 JP2021547654A JP2021547654A JP2022509358A5 JP 2022509358 A5 JP2022509358 A5 JP 2022509358A5 JP 2021547654 A JP2021547654 A JP 2021547654A JP 2021547654 A JP2021547654 A JP 2021547654A JP 2022509358 A5 JP2022509358 A5 JP 2022509358A5
Authority
JP
Japan
Prior art keywords
hydroxypropyl
cyclodextrin
composition
composition according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547654A
Other languages
English (en)
Japanese (ja)
Other versions
JP7446322B2 (ja
JP2022509358A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057784 external-priority patent/WO2020092107A1/en
Publication of JP2022509358A publication Critical patent/JP2022509358A/ja
Publication of JP2022509358A5 publication Critical patent/JP2022509358A5/ja
Application granted granted Critical
Publication of JP7446322B2 publication Critical patent/JP7446322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547654A 2018-10-29 2019-10-24 アルツハイマー病を治療する方法 Active JP7446322B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862752131P 2018-10-29 2018-10-29
US62/752,131 2018-10-29
US201962885053P 2019-08-09 2019-08-09
US62/885,053 2019-08-09
PCT/US2019/057784 WO2020092107A1 (en) 2018-10-29 2019-10-24 Methods for treating alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2022509358A JP2022509358A (ja) 2022-01-20
JP2022509358A5 true JP2022509358A5 (cg-RX-API-DMAC7.html) 2022-10-28
JP7446322B2 JP7446322B2 (ja) 2024-03-08

Family

ID=68583503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547654A Active JP7446322B2 (ja) 2018-10-29 2019-10-24 アルツハイマー病を治療する方法

Country Status (10)

Country Link
US (3) US11925659B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873604B1 (cg-RX-API-DMAC7.html)
JP (1) JP7446322B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084480A (cg-RX-API-DMAC7.html)
CN (1) CN112996562A (cg-RX-API-DMAC7.html)
BR (1) BR112021008139A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114021C (cg-RX-API-DMAC7.html)
ES (1) ES2992137T3 (cg-RX-API-DMAC7.html)
PT (1) PT3873604T (cg-RX-API-DMAC7.html)
WO (1) WO2020092107A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021284155A1 (en) * 2020-06-02 2023-01-05 National University Of Singapore Compositions, their uses in therapy and methods thereof
WO2022051631A1 (en) 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
CA3200988A1 (en) * 2020-11-06 2022-05-12 John Jahangir Alam Treatment of gait dysfunction in neurodegenerative disease
WO2022099094A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Compositions and methods for treating depression
WO2022197640A1 (en) * 2021-03-14 2022-09-22 Massachusetts Institute Of Technology Apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells
EP4433828A1 (en) * 2021-11-18 2024-09-25 Vib Vzw Improved gamma-secretase inhibitor screening assays
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー.ビー.シー. ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法
WO2023191425A1 (ko) * 2022-03-28 2023-10-05 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
KR20250024808A (ko) * 2022-06-13 2025-02-19 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린 제조를 위한 시스템 및 방법
CA3263540A1 (en) * 2022-07-29 2024-02-01 Anavex Life Sciences Corp. Compositions and methods for the prevention of cognitive decline caused by degenerative diseases
US20260124236A1 (en) * 2022-09-30 2026-05-07 Cyclo Therapeutics, Inc. Methods for treating early alzheimer’s disease
WO2025214478A1 (zh) * 2024-04-12 2025-10-16 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US8883494B2 (en) 2003-11-14 2014-11-11 Adil A. KHAN In vitro model for neuronal death
KR101530050B1 (ko) 2007-03-02 2015-06-22 주식회사 노브메타파마 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법
WO2013155485A2 (en) 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin
CA2880880C (en) 2012-08-03 2021-01-26 John Mckew Cyclodextrin for the treatment of lysosomal storage diseases
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
EP3432880A4 (en) * 2016-03-20 2019-12-11 Asdera LLC USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNES AND NEURODEEGENERATIVE DISEASES

Similar Documents

Publication Publication Date Title
JP2019530713A5 (cg-RX-API-DMAC7.html)
AU2012321110B2 (en) Combination treatment
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法(ベムラフェニブ及びmdm2阻害剤)
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
JP2017537105A5 (cg-RX-API-DMAC7.html)
JP2013527132A (ja) 中枢神経系(cns)の自己免疫性脱髄性疾患の治療において使用するためのジアゾキシド
JP7217789B2 (ja) 併存疾患としてアパシーを伴うアルツハイマー病の治療における使用のための5-ht6受容体アンタゴニスト
JP2015172060A5 (cg-RX-API-DMAC7.html)
Rossignol et al. Evolution and treatment of childhood chronic inflammatory polyneuropathy
Serratosa et al. Safety and tolerability of perampanel: a review of clinical trial data
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
JP2020517671A5 (cg-RX-API-DMAC7.html)
JP2026515115A (ja) マントル細胞リンパ腫治療薬の製造における抗cd20抗体-薬物コンジュゲートの使用
JP2019507786A5 (cg-RX-API-DMAC7.html)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
JP2005529152A5 (cg-RX-API-DMAC7.html)
JP2008501023A (ja) 小児患者での癌の治療
KR20240046527A (ko) 암치료를 위한 신규 경구용 약학적 조성물
JP2025511403A5 (cg-RX-API-DMAC7.html)
JP2020172471A (ja) ヒト化抗ヒトcd26抗体を含有する医薬組成物
JP2021516702A (ja) 抗−vegfr−2抗体
JP7445826B2 (ja) 固形腫瘍治療用医薬組成物